Boston Scientific Corporation BSX recently agreed to purchase the majority stake in M.I.Tech Co., Ltd from Synergy Innovation Co., Ltd. This latest investment is aimed at broadening Boston Scientific’s stent portfolio within the broader MedSurg business globally.
The purchase price has been fixed at $230 million per the current exchange rate. The transaction is expected to be closed in the second half of 2022, subject to customary closing conditions.
More on the News
M.I.Tech is a publicly-traded Korean manufacturer and distributor of medical devices for endoscopic and urologic procedures. The company’s HANAROSTENT technology is a family of conformable, non-vascular, self-expanding metal stents. This HANAROSTENT series of M.I.Tech has been distributed by Boston Scientific in Japan since 2015.
RELATED: OrthoPediatrics buys Pega Medical for up to $33M
Financial Terms in Detail
Boston Scientific’s agreement to purchase a 64% stake in M.I.Tech includes a purchase price of KRW 14,500 per share or a total consideration of KRW 291.2 billion or approximately $230 million at current exchange rates, subject to closing adjustments.
The impact of this acquisition on BSX’s GAAP and adjusted earnings per share is expected to be immaterial in 2022.
Importance of the Deal
According to Boston Scientific, M.I.Tech’s product offerings complement the company’s existing stent portfolio, including the differentiated AXIOS Stent and Electrocautery Enhanced Delivery System and the flexible and conformable Agile Esophageal Stent System.
Boston Scientific noted that, in many cases, non-vascular gastrointestinal and airway stent placement is minimally invasive and aids faster patient recovery compared to surgery. M.I.Tech’s HANAROSTENT technology features a unique hook-cross nitinol design intended to provide a natural and flexible fit within a patient’s anatomy as well as flared ends to help prevent stent migration.
BSX’s Inorganic Growth
We are impressed with Boston Scientific’s recent acquisitions that have added numerous products (though many are under development) with immense potential. These, in turn, should help boost the top line in the long term. The company is optimistic about recently acquired Israel-based Lumenis that develops and commercializes energy-based medical solutions. The acquisition expands Boston Scientific’s Urology portfolio with its differentiated laser technology.
Apart from this, Preventice Solutions (which offers new-generation detection algorithms, a broad portfolio with BodyGuardian MINI and establishes a strong position for Boston Scientific in the field of cardiac diagnostics) grew 20% on a full-year pro forma basis in 2021, driven by the company’s differentiated portfolio and strong execution. Within Electrophysiology, the early launch of Farapulse has been progressing well in Europe.
In February 2022, Boston Scientific completed the purchase of Baylis Medical Company for an upfront payment of $1.75 billion. The acquisition is expected to expand the company’s electrophysiology and structural heart product offerings with the addition of the radiofrequency NRG and VersaCross Transseptal Platforms as well as a range of guidewires, sheaths and dilators.
The company closed the acquisition of Devoro during the fourth quarter of 2021 and is currently looking forward to launching its arterial and venous offerings in the second half of 2022.
